Abstract
In this review are described the preclinical and clinical pharmacological data as well as new therapeutic indications for the use of 4-aminopyridine. 4-aminopyridine is a potassium (K+) channel blocker that has a long history and various application areas. It is a chemical agent developed in 1963 as a bird poison. The first approval for clinical application of 4-aminopyridine was in 70’s in Bulgaria, since anesthetists in that country have confirmed its effect as reversal agent for nondepolarizing myorelaxants. The Bulgarian pharmaceutical company Sopharma commersialized 4-aminopyridine under the trade name Pymadin. Since then 4-aminopyridine was extensively studied and in 2010 is approved in the USA for the treatment of walking disabilities in patients with multiple sclerosis. In recent years, data from clinical trials indicated that K-channel blockade may prove to be an appropriate strategy to overcome disturbances in nerve impulses conduction associated with demyelination of the central nervous system.
Highlights
Multiple sclerosis (MS) is the most frequent cause of neurological deficit in young adults (Solari et al 2002)
There is no effective cure for MS, but there are available therapies approved for reduction of the symptoms and progression of the disease
Some of the pharmacological effects of aminopyridines have been known for many years, but only since Bulgarian pharmacologists and anesthetists, based on their experimental and clinical studies, recommended the use of 4-aminopyridine hydrochloride (Pymadin, Sopharma, Bulgaria) for facilitation of neuromuscular transmission
Summary
4-aminopyridine – the new old drug for the treatment of neurodegenerative diseases. Citation: Kostadinova I, Danchev N (2019) Evaluation of kidney function parameters in diabetic rats following virgin coconut oil diet. 4-aminopyridine – the new old drug for the treatment of neurodegenerative diseases
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have